Table 1
Open in new tab

Overview of meta‐analyses, which show hazard ratios for PFS, OS, and odds ratios for ORR on anti‐epidermal growth factor receptor monoclonal antibody therapy by BRAF status for the KRASwt group and (°) for the KRAS unselected group

StudyBRAFmtBRAFwtxBRAFmt/BRAFwt
yBRAFwt/BRAFmt
(n/n BRAFmt) [Ref]PFSOSORRPFSOSORRPFSOSORR
De Roockx (761/36) [4]

3.74

 

[2.44–5.75]

3.03

 

[1.98–4.63]

0.15

 

[0.02–0.51]

Pietrantonio (6,256/469) [31]

0.88

 

[0.67–1.14]

0.91

 

[0.62–1.34]

1.31

 

[0.83–2.08]

Rowlandx (3,186/351) [30]

0.86

 

[0.61–1.21]

0.97

 

[0.67–1.41]

n.d.

0.62

 

[0.50–0.77]

0.81

 

[0.70–0.95]

n.d.

1.39a

 

[0.92–2.08]

1.19a

 

[0.80–1.78]

n.d.
Therkildsenx (1,267/123) [29]

2.95

 

[1.89–4.61]

2.52

 

[1.39–4.56]

0.29

 

[0.16–0.54]

Yuany (4,616/343) [32]

0.29

 

[0.19–0.43]

0.26

 

[0.20–0.36]

0.31

 

[0.18–0.53]

Xux (2,875/246) [36]

2.41

 

[1.23–4.71]

2.74°

 

[2.31–3.52]

0.26

 

[0.07–0.98]

Wangx (1,352/74) [37]

2.78

 

[1.62–4.76]

2.54

 

[1.93–3.32]

0.27

 

[0.10–0.70]

Cuix (1,245/126) [38]n.d.n.d.

0.43

 

[0.16–0.75]

StudyBRAFmtBRAFwtxBRAFmt/BRAFwt
yBRAFwt/BRAFmt
(n/n BRAFmt) [Ref]PFSOSORRPFSOSORRPFSOSORR
De Roockx (761/36) [4]

3.74

 

[2.44–5.75]

3.03

 

[1.98–4.63]

0.15

 

[0.02–0.51]

Pietrantonio (6,256/469) [31]

0.88

 

[0.67–1.14]

0.91

 

[0.62–1.34]

1.31

 

[0.83–2.08]

Rowlandx (3,186/351) [30]

0.86

 

[0.61–1.21]

0.97

 

[0.67–1.41]

n.d.

0.62

 

[0.50–0.77]

0.81

 

[0.70–0.95]

n.d.

1.39a

 

[0.92–2.08]

1.19a

 

[0.80–1.78]

n.d.
Therkildsenx (1,267/123) [29]

2.95

 

[1.89–4.61]

2.52

 

[1.39–4.56]

0.29

 

[0.16–0.54]

Yuany (4,616/343) [32]

0.29

 

[0.19–0.43]

0.26

 

[0.20–0.36]

0.31

 

[0.18–0.53]

Xux (2,875/246) [36]

2.41

 

[1.23–4.71]

2.74°

 

[2.31–3.52]

0.26

 

[0.07–0.98]

Wangx (1,352/74) [37]

2.78

 

[1.62–4.76]

2.54

 

[1.93–3.32]

0.27

 

[0.10–0.70]

Cuix (1,245/126) [38]n.d.n.d.

0.43

 

[0.16–0.75]

Four meta‐analyses included only or primarily RCTs [29–31, 38] three included retrospective and prospective studies [32, 36, 37] and one included only retrospective data [4].

bBased on re‐calculation performed by the authors of this proposal.

Abbreviations: KRAS, Kirsten rat sarcoma viral oncogene homolog; mt, mutated; n, number of patients; n BRAFmt, number of patients with a BRAF mutation; n.d., not described; ORR, overall response rate; OS, overall survival; PFS, progression‐free survival; RCT, randomized controlled trial; wt, wild type.

Table 1
Open in new tab

Overview of meta‐analyses, which show hazard ratios for PFS, OS, and odds ratios for ORR on anti‐epidermal growth factor receptor monoclonal antibody therapy by BRAF status for the KRASwt group and (°) for the KRAS unselected group

StudyBRAFmtBRAFwtxBRAFmt/BRAFwt
yBRAFwt/BRAFmt
(n/n BRAFmt) [Ref]PFSOSORRPFSOSORRPFSOSORR
De Roockx (761/36) [4]

3.74

 

[2.44–5.75]

3.03

 

[1.98–4.63]

0.15

 

[0.02–0.51]

Pietrantonio (6,256/469) [31]

0.88

 

[0.67–1.14]

0.91

 

[0.62–1.34]

1.31

 

[0.83–2.08]

Rowlandx (3,186/351) [30]

0.86

 

[0.61–1.21]

0.97

 

[0.67–1.41]

n.d.

0.62

 

[0.50–0.77]

0.81

 

[0.70–0.95]

n.d.

1.39a

 

[0.92–2.08]

1.19a

 

[0.80–1.78]

n.d.
Therkildsenx (1,267/123) [29]

2.95

 

[1.89–4.61]

2.52

 

[1.39–4.56]

0.29

 

[0.16–0.54]

Yuany (4,616/343) [32]

0.29

 

[0.19–0.43]

0.26

 

[0.20–0.36]

0.31

 

[0.18–0.53]

Xux (2,875/246) [36]

2.41

 

[1.23–4.71]

2.74°

 

[2.31–3.52]

0.26

 

[0.07–0.98]

Wangx (1,352/74) [37]

2.78

 

[1.62–4.76]

2.54

 

[1.93–3.32]

0.27

 

[0.10–0.70]

Cuix (1,245/126) [38]n.d.n.d.

0.43

 

[0.16–0.75]

StudyBRAFmtBRAFwtxBRAFmt/BRAFwt
yBRAFwt/BRAFmt
(n/n BRAFmt) [Ref]PFSOSORRPFSOSORRPFSOSORR
De Roockx (761/36) [4]

3.74

 

[2.44–5.75]

3.03

 

[1.98–4.63]

0.15

 

[0.02–0.51]

Pietrantonio (6,256/469) [31]

0.88

 

[0.67–1.14]

0.91

 

[0.62–1.34]

1.31

 

[0.83–2.08]

Rowlandx (3,186/351) [30]

0.86

 

[0.61–1.21]

0.97

 

[0.67–1.41]

n.d.

0.62

 

[0.50–0.77]

0.81

 

[0.70–0.95]

n.d.

1.39a

 

[0.92–2.08]

1.19a

 

[0.80–1.78]

n.d.
Therkildsenx (1,267/123) [29]

2.95

 

[1.89–4.61]

2.52

 

[1.39–4.56]

0.29

 

[0.16–0.54]

Yuany (4,616/343) [32]

0.29

 

[0.19–0.43]

0.26

 

[0.20–0.36]

0.31

 

[0.18–0.53]

Xux (2,875/246) [36]

2.41

 

[1.23–4.71]

2.74°

 

[2.31–3.52]

0.26

 

[0.07–0.98]

Wangx (1,352/74) [37]

2.78

 

[1.62–4.76]

2.54

 

[1.93–3.32]

0.27

 

[0.10–0.70]

Cuix (1,245/126) [38]n.d.n.d.

0.43

 

[0.16–0.75]

Four meta‐analyses included only or primarily RCTs [29–31, 38] three included retrospective and prospective studies [32, 36, 37] and one included only retrospective data [4].

bBased on re‐calculation performed by the authors of this proposal.

Abbreviations: KRAS, Kirsten rat sarcoma viral oncogene homolog; mt, mutated; n, number of patients; n BRAFmt, number of patients with a BRAF mutation; n.d., not described; ORR, overall response rate; OS, overall survival; PFS, progression‐free survival; RCT, randomized controlled trial; wt, wild type.

Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close